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ABSTRACT
Loss of the maintenance of genetic material is a crit-
ical step leading to tumorigenesis. It was reported
that overexpression of Aurora-A and the constitutive
activation of the epidermal growth factor (EGF)
receptor (EGFR) are implicated in chromosome
instability. In this study, we examined that when
cells treated with EGF result in centrosome amplifi-
cation and microtubule disorder, which are critical
for genetic instability. Interestingly, the expression
of Aurora-A was also increased by EGF stimulus.
An immunofluorescence assay indicated that EGF
can induce the nuclear translocation of EGFR.
Chromatin immunoprecipitation (ChIP) and re-ChIP
assays showed significant EGF-induced recruitment
of nuclear EGFR and signal transducer and activator
of transcription 5 (STAT5) to the Aurora-A promoter.
A co-immunoprecipitation assay further demon-
strated that EGF induces nuclear interaction
between EGFR and STAT5. A small interfering
(si)RNA knockdown assay also showed that EGFR
and STAT5 are indeed involved in EGF-increased
Aurora-A gene expression. Altogether, this study
proposes that the nuclear EGFR associates with
STAT5 to bind and increase Aurora-A gene expres-
sion, which ultimately may lead to chromosome
instability and tumorigenesis. The results also
provide a novel linkage between the EGFR signaling
pathway and overexpression of Aurora-A in tumor-
igenesis and chromosome instability.
INTRODUCTION
Genetic instability is a major event in tumorigenesis.
Proteins involved in the cell-cycle checkpoint mechanism
or controlling chromosome replication and separation
during cell division are believed to be important for main-
taining genome integrity and ﬁdelity. Among them, the
Aurora kinase family is critical for various events in mito-
sis and/or meiosis. They play important roles in cell divi-
sion, including the control of centrosome and spindle
function, involvement of kinetochore–microtubule inter-
actions and cytokinesis. Three family members of
Aurora kinases, Aurora-A, -B and -C were discovered in
mammals. Human Aurora-A is a centrosomal-associated
serine/threonine kinase, which is involved in cell-cycle pro-
gression, cell survival and malignant transformation.
Aurora-A is located on chromosome 20q13.2, a region
commonly ampliﬁed in malignancies, such as melanomas
and cancers of the breast, colon, pancreas, ovary, bladder,
liver and stomach. It was reported that Aurora-A is over-
expressed in many cancer cells (1–3), suggesting that
Aurora-A is involved in tumorigenesis. In proliferating
cancer cell lines, the expression of Aurora-A, including
messenger RNA (mRNA), protein levels and kinase activ-
ities, is under cell-cycle control. Interest in Aurora has
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A into rodent Rat1 and NIH3T3 ﬁbroblast cell lines is
suﬃcient to induce colony formation in culture and
tumors in nude mice (1,4), thus establishing Aurora-A as
a bona ﬁde oncogene (4–6). Dysregulation of Aurora
kinases has been linked to tumorigenesis. Therefore, the
control of Aurora-A expression and activation is an
important event for normal cell-cycle progression (7).
Previous studies indicated that the increased expression
of Aurora-A in cancers occurs through gene ampliﬁcation,
RNA transcriptional upregulation, or protein stabilization
(4). Among them, many studies focused on the regulation
of protein stability. In addition, several lines of evidence
have shown that the E4TF1/hGABP (GA-binding pro-
tein) transcription factor plays an important role in the
transcriptional regulation of Aurora-A in a cell-cycle-
dependent manner (8,9), and the TRAP220/MED1
(thyroid hormone receptor-associated protein complex
component/methyl-CpG binding endonuclease) directly
interacts with GABP to regulate Aurora-A gene expression
in HeLa cells (10). Furthermore, the DUSP6/MKP-3
(dual speciﬁcity phosphatase 6/MAPK phosphatase-3, a
candidate tumor suppressor gene and a speciﬁc phospha-
taseforMAPK1),candownregulateAurora-Ageneexpres-
sion in pancreatic cancer (11). But until now, the detailed
transcriptional regulatory mechanism of Aurora-A in
cancer cells remains largely uncertain.
The epidermal growth factor receptor (EGFR) is a
transmembrane glycoprotein containing tyrosine kinase
activity. Upon growth factor stimulation, EGFR activates
and transfers extracellular signals into cytoplasmic
molecules such as mitogen-activated protein kinase
(MAPK), phospholipase C-g (PLCg) and phosphatidyli-
nositol-3-OH (PI-3) kinase and regulates target gene
expressions (12–16). Recently, many studies have shown
that the nuclear localization of the EGFR is strongly cor-
related with highly proliferating tissues (15,17–24). The
nuclear EGFR can recognize AT-rich sequence sites
(ATRSs) of target gene promoters and activate gene
expression. Therefore the function of the nuclear EGFR
is that of a transcriptional activator which regulates gene
expression required for cell proliferation (21,23), for
example cyclin D1 (21), inducible nitric oxide synthase
(23) and cyclooxygenase-2 (25). Interestingly, the EGFR
lacks a DNA-binding domain (23), and the nuclear
EGFR physically interacts with other transcriptional
molecules, such as the signal transducer and activator of
transcription 3 (STAT3) (23) and E2F1 (26), to activate
gene expression. Most importantly, it was reported that
the overexpression and constitutive activation of EGFR
in cancer cells may be associated with chromosomal
instability (27,28), a phenotype just like the overexpressed
Aurora-A in cancers (29).
In this study, we demonstrate that EGF stimulation
results in centrosome ampliﬁcation and microtubule dis-
order as well as the induction of Aurora-A overexpression.
The ligand-activated EGFR is translocated into the
nucleus and then targets the ATRSs of the Aurora-A pro-
moter through interacting with STAT5. This is the ﬁrst
report to correlate the overexpression of Aurora-A and
the nuclear EGFR in malignant cancer cells, and hence
may provide a target for cancer therapy.
MATERIALS AND METHODS
Cell cultureand drugtreatment
A431, 293T, MCF7, MDA-MB-231 and MDA-MB-468
cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM, GIBCO, Invitrogen, Carlsbad, CA),
LS174T cells were cultured in Minimum Essential
Medium Alpha medium (MEM-a medium, GIBCO).
CHO cells were cultured in F12 medium (GIBCO).
Culture media were supplemented with 10% fetal bovine
serum, 100mg/ml streptomycin and 100 U/ml penicillin. In
this series of experiments, cells were treated with 60ng/ml
(10nM) EGF in optimal serum-free conditions.
siRNA transfection and STAT5overexpression
siRNA oligos for knockdown of endogenous STAT5 pro-
teins were prepared by using the siRNA SMARTpool
from Dharmacon (M-005169-02-0005 for STAT5A and
M-010539-01-0005 for STAT5B, Dharmacon RNA
Technologies, Lafayette, CO), and Ambion (catalog
number: 138787 for STAT5A, Ambion, The RNA
Company, Austin, TX). EGFR siRNA oligos were pur-
chased from QIAGEN (Hs_EGFR_12_HP Validated
siRNA). STAT5A and STAT5B cDNA were cloned
from HeLa complementary (c)DNA by a PCR (STAT5A
forward primer: 50-CATAAGCTTATGGCGGGCTGG
ATCCAGGCC-30 and reverse primer: 50-CAACTCGAG
TGAGAGGGAGCCTCTGGCAGA-30; and STAT5B
forward primer: 50-CGGAAGCTTATGGCTGTGTGG
ATACAAGCT-30 and reverse primer: 50-GTTCTCGAG
CGATTGTGCTGTCGGGAT-30), and constructed into
a pcDNA3.1
TM/myc-His expression vector (Invitrogen,
Carlsbad, CA) using the HindIII and XhoI restriction
enzyme sites. The siRNA and STAT5 expression vectors
were transfected into cells using LipofectAMINE 2000
(Invitrogen) according to the manufacturer’s instructions.
Quantitative reverse-transcription polymerase
chain reaction (RT-PCR) and RT-PCR
Total RNA from cultured cells was prepared from TriZole
reagent (Invitrogen) as described by the manufacturer’s
instructions. For the RT-PCR, 3mg of total RNA was
used to generate cDNA by reverse transcriptase III
(Invitrogen) followed by the PCR (Aurora-A forward:
50-ATGGACCGATCTAAAGAAAAC-30 and reverse:
50-CGATTCCTAAGACTGTTTGC-30; EGFR forward:
50-CATAGTCAGCAGTGACTTTCTC-30 and reverse:
50-GTTACACACTTTGCGGCAAGG-30; and GAPDH
forward: 50-CCATCACCATCTTCCAGGAG-30 and
reverse: 50-CCTGCTTCACCACCTTCTTG-30). For the
quantitative real-time RT-PCR, cDNA synthesis was per-
formed using the TITANIUM One-Step RT-PCR kit
(Clontech, Palo Alto, CA) containing SYBR Green I
(BioWhittaker Molecular Applications; BMA, Rockland,
ME). In brief, ﬁrst-strand cDNA was synthesized at 508C
for 60min, followed by a 10-min denaturation at 958C.
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following conditions for 35 cycles: 958C for 15s, 608C
for 15s and 688C for 20s. The sequences of primers
used for RT-PCR were as follows: human Aurora-A for-
ward: 50-AATGCCCTGTCTTACTGTCATTC-30 and
reverse: 50-TCCAGAGATCCACCTTCTCATC-30; and
human RPL13A forward: 50-CCTGGAGGAGAAGAG
GAAAGAGA-30 and reverse: 50-TTGAGGACCTCTG
TGTATTTGTCAA-30. Real-time ﬂuorescence monitor-
ing and the melting curve analysis were performed with
LightCycler according to the manufacturer’s recommen-
dations (Roche Molecular Diagnostics, Lewes, East
Sussex, UK). Negative controls containing no RNA tem-
plate were included in each experiment. A melting curve
was created at the end of the PCR cycle to conﬁrm that a
single product had been ampliﬁed. Data were analyzed
by LightCycler software version 3.5 (Roche Molecular
Diagnostics) to determine the threshold cycle (Cp) above
the background for each reaction. The relative transcript
amount of the target gene, calculated using standard
curves of serial RNA dilutions, was normalized to that
of RPL13A of the same RNA.
Reporter assay
Cells were transfected with wild type or mutated Aurora-A
promoter (–968 +124) luciferase construct (pGL2-
Aurora-A promoter) by LipofectAMINE 2000
(Invitrogen) according to the manufacturer’s instructions
with a slight modiﬁcation. Cells are replated 24h before
transfection at an optimal cell density in 2ml of fresh
culture medium in a 6-well plate. As a transfection eﬃ-
ciency control, the Renilla luciferase reporter plasmid,
phRG-TK, was co-transfected into cells. Twenty-four
hours following transfection, cells were serum-starved
for 24h, stimulated with 60ng/ml (10nM) EGF under
serum-free condition for various times, harvested and sub-
jected to the luciferase assay using the dual-luciferase
reporter assay kit (Promega, Madison, WI).
Normalization with the Renilla luciferase activity, mean
luciferase activities, and standard deviations were derived
from three independent experiments. For investigating the
eﬀect of STAT5A and EGFR, the Myc-STAT5A or/and
the EGFR expression vector—pCO11-EGFR was/were
co-transfected with pGL2-Aurora-A promoter.
Preparation of cell lysates and cell fractions
For total cell lysates, cells from 10-cm plastic dishes were
washed twice with PBS and lysed with RIPA buﬀer
[50mM Tris–HCl (pH 7.5), 150mM NaCl, 0.1% NP-40,
0.5% sodium deoxycholate, 1mM EDTA and 2mM
EGTA] containing 1mM sodium orthovanadate, 1mM
phenylmethylsulfonyl ﬂuoride, 10mg/ml leupeptin and
10mg/ml aprotinin. The lysates were centrifuged at
12000 g for 5min. The supernatants were collected
and stored at –708C until used.
For nuclear extracts, cells were washed twice with PBS
and scraped in 500ml of PBS. Cells were collected by cen-
trifuging at 7500 g for 30s, resuspended in 400mlo f
buﬀer A [10mM Hepes (pH 7.9), 1.5mM MgCl2 and
10mM KCl] and placed on ice for 10min. Nuclei were
pelleted by centrifugation at 7500 g for 30s, and the
resulting supernatant formed the cytosolic fraction. The
nuclear pellets were resuspended in 100ml of buﬀer C
[20mM Hepes (pH 7.9), 1.5mM MgCl2, 0.2mM EDTA,
420mM NaCl and 25% (v/v) glycerol] and placed on ice
for 20min. The suspension was centrifuged at 7500 g for
2min, and the resulting supernatant was termed the
nuclear fraction. The cytosolic and nuclear fractions
were stored at –708C until used. Buﬀers A and C con-
tained 0.5mM dithiothreitol, 2mg/ml leupeptin, 1mM
orthovanadate, 2mg/ml pepstatin A and 0.5mM phenyl-
methylsulfonyl ﬂuoride.
Co-immunoprecipitation assay and
immunoblotting analysis
For the co-immunoprecipitation assay, nuclear extracts
were puriﬁed from EGF-treated A431 cells, and then incu-
bated with anti-EGFR antibodies or normal rabbit immu-
noglobulin G (IgG) in an immunoprecipitation buﬀer
[20mM Hepes (pH 7.9), 120mM NaCl, 1.5mM MgCl2,
0.2mM EDTA, 25% glycerol, 0.5mM phenylmethylsulfo-
nyl ﬂuoride, 1mM orthovanadate, 2mg/ml pepstatin A
and 2mg/ml leupeptin] under gentle shaking at 48C over-
night, and then Protein A agarose beads were added and
incubated for a further 2h. Beads were washed three times
with immunoprecipitation buﬀer and two times with PBS.
The immunoprecipitation complexes were resolved by
SDS–PAGE and subjected to immunoblotting analysis
by anti-EGFR polyclonal antibodies (pAbs) or anti-
STAT5 pAbs.
Indirect immunofluorescence assay
andconfocal microscopy
The immunoﬂuorescence assay was performed as pre-
viously described (30). Brieﬂy, cells were grown on cover-
slips and ﬁxed with 3.7% formaldehyde at room
temperature for 10min. The ﬁxed cells were then probed
with anti-Aurora-A pAbs (ab1287, Abcam, Cambridge,
MA) and an anti-g-tubulin mAb (GTU88, Sigma,
St Louis, MO), or anti-a-tubulin mAb (mAb) (DM1A-
FITC, Sigma). DNA was stained with DAPI (Sigma).
After the ﬁrst antibody incubation, these immunoactive
probes were detected with Alexa 568 (Molecular Probes,
Cincinnati, OH), a Texas Red-conjugated goat anti-mouse
IgG, and Alexa 488 (Molecular Probes), and FITC-
conjugated goat anti-rabbit IgG. Coverslips were mounted
and observed with a laser scanning confocal system
(FV1000, Olympus, PA, USA).
Chromatin immunoprecipitation (ChIP) and
sequential ChIP assay
Cells were crosslinked with 1% formaldehyde at 378C for
15min, washed twice with PBS, lysed with L1 buﬀer
[50mM Tris–HCl (pH 8.0), 2mM EDTA, 0.1% NP-40
and 10% glycerol], and then resuspended with L2 buﬀer
[50mM Tris–HCl (pH 8.0), 5mM EDTA and 1% SDS].
The lysates were sonicated to shear the size of the DNA to
around 500bp. Sonicated extracts were diluted 10-fold
with a dilution buﬀer [50mM Tris–HCl (pH 8.0), 0.5mM
EDTA, 0.5% NP-40 and 0.2M NaCl]. After pre-cleaning
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Sepharose, 200mg of the extracts was used for immunopre-
cipitation assay. The immunoprecipitated complexes were
pelleted and washed with high-salt and low-salt buﬀers
three times each. For ChIP assay, the DNA–protein com-
plex was then eluted in an elution buﬀer (1X TE buﬀer
containing 1% SDS) with rotation at room temperature
for 15min, and the immune complex crosslinking was
reversed by heating at 658C overnight, followed by treat-
ment with 100mg/ml proteinase K at 508C for 1h. DNA
was extracted twice with phenol/chloroform and precipi-
tated with ethanol. The pellet was redissolved in H2O and
subjected to PCR ampliﬁcation using speciﬁc primers to
the Aurora-A promoter, which were 50-CTGTTGCTT
CACCGATAAATGGC-30 and 50-CTCTAGCTAGAAA
GCCGATTGGC-30. For sequential ChIP assay, the
DNA–protein complex was eluted from the protein A
Sepharose beads by incubating with 10mM DTT in 378C
for 30min twice. After diluted 10-fold with dilution buﬀer,
the eluted mixture was used to perform the second immu-
noprecipitation assay. L1, L2 and dilution buﬀer all con-
tained 0.5mM phenylmethylsulfonyl ﬂuoride, 1mM
orthovanadate, 2mg/ml pepstatin A, 2mg/ml leupeptin,
5mM sodium ﬂuoride and 1mg/ml aprotinin.
DNA affinity precipitation assay(DAPA)
The DNA aﬃnity-binding assay was performed by mixing
200mg of nuclear extract proteins, 2mg of biotinylated
Aurora-A nucleotides and 20ml of streptavidin–agarose
beads (4%) with a 50% slurry. The mixture was incubated
at 48C for 1h with rotation. Beads were pelleted and
washed with cold PBS containing 0.1% NP-40 three
times. The binding proteins were eluted by SDS loading
buﬀer and analyzed by Western blot analysis with speciﬁc
antibodies.
RESULTS
The EGF inducescentrosomes amplification and
microtubule disorder in A431 cells
It is well recognized that centrosome abnormalities are
one of the main reasons for chromosomal instability
through the development of multipolar mitotic spindles
(31). It was also reported that activation of the EGFR
may result in genetic instability (27,28). These descriptions
prompted us to investigate whether activation of the
EGFR results in chromosomal instability through abnor-
mal centrosomes. In order to examine this possibility, the
biological eﬀects of the EGF in EGFR-overexpressed
A431 cells were evaluated by an immunoﬂuorescence
assay. Serum-deprived A431 cells were treated with the
EGF for 3 or 24h, and then re-cultured in growth
medium for another 24h to allow the cell cycle to pro-
gress. These EGF-treated A431 cells were doubly stained
with g-tubulin (Figure 1A, red) and Aurora-A (Figure 1A,
green) antibodies, both of which are well-known centro-
somal proteins. The data revealed that the EGF-induced
centrosomes ampliﬁcation in A431 cells (Figure 1A). The
situation with the microtubule cytoskeleton was also
examined using anti-a-tubulin antibody, and the results
indicated that the microtubule network was disarranged
(Figure 1B). Both the centrosome number and microtu-
bule organization in A431 cells without EGF treatment
were normal (Figure 1C). The quantitative results of
EGF-induced centrosomes ampliﬁcation are shown in
Table 1. These results indicated that the EGF can
induce centrosomes ampliﬁcation and microtubule disor-
der in A431 cells. Besides, the result in Figure 1A also
showed that Aurora-A protein is increased.
The EGF increases Aurora-A geneexpression in
EGFR-expressing cell lines
We then analyzed the eﬀect of the EGF on Aurora-A
protein expression in three cultured cell lines: A431,
MDA-MB-231 and MDA-MB-468. The data revealed
that after EGF stimulation, the expression of Aurora-A
kinase increased (Figure 2A). Because it is well recognized
that the EGF transduces its signaling through binding
with the EGFR, expressions of the EGFR and Aurora-
A were examined in six cultured cancer cell lines by a
RT-PCR assay. The results indicated that the expression
of Aurora-A mRNA is increased in four of these cell
lines, which express the EGFR, under EGF treatment
(Figure 2B). Data of the quantitative real-time RT-PCR
further showed that Aurora-A mRNA was indeed elevated
under EGF stimulation in A431 cells (Figure 2C). The
promoter activity of the Aurora-A gene was also enhanced
in A431 cells but not in 293T or MCF7 cells without
EGFR expression under EGF stimulation (Supplementary
Figure 1). Both the promoter activity and protein expres-
sion of Aurora-A were increased in a time-dependent
(Figure 2D) manner with EGF treatment. These data
demonstrate that the Aurora-A promoter is activated by
EGF stimulation in EGFR-expressing cultured cell lines.
Activation of theEGFR isrequired forEGF-induced
Aurora-A expression
It is known that activation of the EGFR is highly corre-
lated with malignant cancers, and the overexpression of
the Aurora-A oncogene plays a pioneering role in the early
stage of tumorigenesis (3). Until now, no studies have
clariﬁed the possible relationships between activation of
the EGFR and overexpression of Aurora-A in cancer
cells. Our data demonstrate that EGF treatment can
increase Aurora-A expression in EGFR-expressing cell
lines (Figure 2). To conﬁrm this phenomenon and verify
that activation of the EGFR does increase Aurora-A gene
expression, A431 cells were treated with the EGF, and the
activation status of the EGFR and the expression of
Aurora-A were then analyzed. As shown in Figure 3A,
the EGFR was activated (as indicated by the arrow) and
expression of Aurora-A was also increased under EGF
stimulation. When cells were pretreated with the EGFR
inhibitor, AG1478, the expression of Aurora-A was no
longer increased by EGF stimulation (Figure 3A).
Altogether, these results indicate that EGF treatment
can result in EGFR activation and increased expression
of Aurora-A.
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anuclear pathway
It was established that when the EGFR is activated,
ligand–EGFR complexes undergo two fates: endocyto-
sis/degradation or recycling to the cell membrane for sub-
sequent activation (32). Endocytosis/degradation of the
activated EGFR plays an essential role in its anti-tumor
eﬀects (33). Recently, it was reported that the EGFR can
be activated and then translocated into the nucleus as a
transcriptional activator (21). The nuclear translocation of
the EGFR is highly correlated with malignancy (21). The
EGFR carries out its biological eﬀects via two signaling
pathways: the cytoplasmic/traditional pathway and the
nuclear pathway (34). Here, when cells were treated with
the EGF, the EGFR still remained at a high level
(Figure 3B, ‘T’ part) and existed in nucleus fractions
γ-tubulin DAPI superimposed Aurora-A
A431
HeLa
A
B
A431
HeLa
α-tubulin α-tubulin + DAPI
γ-tubulin DAPI
α-tubulin DAPI
C
Figure 1. Eﬀect of EGF on genetic instability. (A, B) A431 cells were treated with the EGF (10nM) for 24h, and then the EGF was washed out, and
cells were further cultured in normal culture medium for another 24h to allow them to undergo one cell cycle. The immunoﬂuorescence assay of cells
was then performed using anti-Aurora-A antibodies (green), anti-g-tubulin antibody (red) and DAPI (blue, a DNA-speciﬁc dye) (A), or an a-tubulin
antibody (green) (B). HeLa cells were used as a staining control. Scale bars, 10 mm. (C) The centrosome number and microtubule organization are
normal in EGF-untreated A431 cells. Serum-starvated A431 cells were further cultured in growth medium for 24h, and then the immunoﬂourescence
assay was performed by using anti-g-tubulin antibody (red) and anti-a-tubulin antibody (green) for monitoring the centrosome number and
microtubule organization status.
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MDA-MB-468 cells. These results suggest that the
ligand-activated EGFR did not undergo the endocytosis/
degradation process, but went through the nuclear path-
way. This implies that the activated EGFR mostly
passes through the nuclear pathway to induce Aurora-A
expression. Moreover, anti-phospho-EGFR antibodies
(phospho-tyrosine 845) were used to further conﬁrm the
nuclear localization of the activated EGFR in these cells
(data not shown). These results indicate that the signaling
pathway involved in the EGF-induced Aurora-A gene
expression in A431 cells (also in MDA-MB-231 and
MDA-MB-468) may be the nuclear EGFR pathway.
The nuclear EGFR can target theAurora-A promoter
upon EGF stimulation
In order to verify the physiological role of the nuclear
EGFR in the increased expression of Aurora-A, the pro-
moter region of Aurora-A was analyzed to conﬁrm the
potential EGFR-targeting sites (AT-rich sequences,
ATRSs): TNTTT or TTTNT (21). Sequence analysis
revealed that there are ﬁve putative ATRSs on the prox-
imal region of the Aurora-A promoter (between -576 and
+124, ATRS-1 5, Figure 4A). The distance between
ATRS-1 and ATRS-2 is only ﬁve nucleotides. To directly
verify whether the nuclear EGFR can bind to and activate
the Aurora-A promoter, we performed an in vivo ChIP
assay. The nuclear EGFR was recruited to the Aurora-A
promoter by EGF stimulation (Figure 4B). Next, we iden-
tiﬁed the regulatory elements responsible for nuclear
A
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Figure 2. EGF induces Aurora-A gene expression in cultured cells. Serum-deprived cells treated with (+) or without (–) the EGF (10nM) were
analyzed by (A) Western blot analysis, (B) RT-PCR and (C) real-time RT-PCR. The expression of Aurora-A was enhanced by EGF stimulation only
in EGF receptor (EGFR)-expressing A431, LS174T, MDA-MB-231 and MDA-MB468 cells but not 293T and MCF7. The quantitative results of A
and B are shown below. The time point for EGF treatment in A and B is 24h. (D) The time-dependent activation of Aurora-A promoter was
measured by a dual reporter assay system, and the Aurora-A protein expression levels at the indicated time points were analyzed by Western blot
analysis. The quantitative result of the Western blot is shown at the side.
Table 1. The degree of centrosomes ampliﬁcation in counted cells
A431 Centrosomes ampliﬁcation
+EGF 3h 47.59% (35/74) moderate
+EGF 24h 60.56% (43/71) excessive
 EGF 24h 6.60% (7/106)
Each static results were calculated in diﬀerent ﬁeld of a coverslip. Three
independent experiments were performed to conform the results.
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stimulation by a DNA-aﬃnity precipitation assay
(DAPA). Four probes containing the ATRSs were
designed to assay the binding of the nuclear EGFR,
among which probe WT1 2 contains two putative
ATRS sites, ATRS-1 and ATRS-2. The results indicated
that only WT1 2 (ATRS-1 and ATRS-2) and WT4
(ATRS-4) could recruit the nuclear EGFR but not the
WT3 (ATRS-3), WT5 (ATRS-5) (data not shown),
ATRS-1 2 mutants (mt1-1 and mt1-2) or ATRS-4
mutants (mt4) (Figure 4B). These data revealed that the
nuclear EGFR may activate expression of the Aurora-A
gene through binding with ATRS-1 2 and ATRS-4.
The nuclear EGFR cooperates withSTAT5 and targetsthe
Aurora-A promoter to regulate its expression
Because of a lack of a DNA-binding domain, the nuclear
EGFR need to cooperate with speciﬁc transcription
factors to target the gene promoter region (23). Analysis
of the DNA sequences of the ﬁve proximal ATRSs of
the Aurora-A promoter revealed that three of them con-
tain the consensus of STAT protein-binding sites
(ATRS-2, ATRS-4 and ATRS-5, Figure 4C). The DAPA
analysis showed that STAT5 is associated with probe
WT1 2 (ATRS-1 and ATRS-2), and WT4 (ATRS-4)
but not WT5 (ATRS-5), ATRS-1 and -2 mutants
AG1478 (10µM) D D +
EGF (10nM) −−
+
+ + −
−
Aurora-A
EGFR
Sp1
D: DMSO control
A
A431 MDA-MB-231 MDA-MB-468
EGF
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α-tubulin 
TN E
EGFR
TN E TN E
B
Sp1
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Figure 3. Activation of the EGFR is required for EGF-induced Aurora-A expression. (A) A431 cells were pretreated with 10 mM AG1478 (an EGFR
inhibitor) for 30min prior to EGF stimulation. Total cell lysates were subjected to an immunoblot assay with the indicated antibodies. D, DMSO.
Immunoblotting of the Sp1 transcription factor was used as a loading control. Arrow indicates the activated/phosphorylated EGFR, which presents
a band shift. (B) Subcellular localization of the EGFR. Nuclear fractions from A431, MDA-MB-231 and MDA-MB-468 cells were puriﬁed, and then
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Figure 4. The nuclear EGFR/STAT5 complex is recruited to the Aurora-A promoter and regulates gene expression. (A) Five predicted EGFR-
targeting sites (the ATRS-1 5) are located in the proximal region of the Aurora-A promoter. This graph shows the wild-type Aurora-A promoter
region from –986 to +124. The black oblongs mean the putative ATRSs, and the gray oblongs mean the ATRSs contain the consensus STAT
protein-binding sequences. ATRS-1: –479   –475; ATRS-2: –469   –465; ATRS-3: –260   –256; ATRS-4: –206   –201; ATRS-5: –15   –11.
(B) A431 cells were treated with (+) or without (–) EGF (10nM) for 30min, and then lysed and performed the in vivo ChIP assay by using anti-
EGFR antibodies (left panel and Figure 4D, lane 5). The nuclear proteins were mixed with biotin-labeled oligonucleotides to perform the DNA-
aﬃnity precipitation assay (DAPA) (right panel). After incubation, the protein-bound probes were precipitated and subjected to immunoblot analysis
with anti-EGFR antibodies. The nucleotides sequences of ATRS1-2 (WT1 2) and ATRS-4 (WT4) and their mutants (mt1-1, mt1-2 and mt4, the
italic letters are the mutated nucleotide sequences) are shown in the upper panel. (C) The consensus signal transducer and activator of transcription
(STAT) protein-binding sequences (dashed-line box) within AT-rich sequences sites (ATRSs) (solid-line box) of the Aurora-A promoter are shown in
the upper panel. Association of STAT5 with the Aurora-A promoter ATRSs was evaluated by DAPA as described in Figure 4B. (D)A nin vivo ChIP
assay demonstrated EGF-induced STAT5 recruitment (lanes 2 and 7). Cells were treated with (+) or without (–) EGF (10nM) for 30min, and the
EGFR/STAT5 complex targeting the Aurora-A promoter was detected by the sequential ChIP assay (lane 8). Following the ﬁrst immunopre-
cipitation with anti-EGFR antibodies, the EGFR–DNA complex was eluted and subjected to the second immunoprecipitation with anti-STAT5
antibodies. The quantitative result of IgG, STAT5 ChIP assay and sequential ChIP (lane 6 8) were showed below. Lane 3 is an input control.
(E) The transcriptional activity of Aurora-A promoter ATRS mutants. A431 cells were transfected with the indicated mutant constructs. After serum
starvation, cells were treated with (+) or without (–) EGF (10nM) for 18h, and the promoter activity of Aurora-A was then measured by a dual
reporter assay system. The upper panel shows the wild-type Aurora-A promoter region from –986 to +124. The black oblongs mean the putative
ATRSs, the gray oblongs mean the ATRS contain the consensus STAT protein-binding sequences, and the white oblongs are the mutated ATRSs.
IgG, normal rabbit IgG. *P<0.05.
4344 Nucleic Acids Research, 2008, Vol. 36, No. 13(mt1-1 and mt1-2), or the ATRS-4 mutant (mt4)
(Figure 4C). The ChIP assay further demonstrated that
STAT5 (Figure 4D) can be recruited to the Aurora-A pro-
moter upon EGF stimulation. Although it was reported
that STAT3 (23) or E2F1 (26) can interact with the
EGFR in activating gene expression, the ChIP assay and
DAPA analysis indicated that the two transcription factors
are not involved in EGF-induced Aurora-A gene expres-
sion (data not shown). The association of the nuclear
EGFR/STAT5 complex with the Aurora-A promoter was
directly demonstrated by the sequential ChIP assay
(Figure 4D). The reporter assay further revealed that
ATRS-2 and ATRS-4 are important for EGF-induced
Aurora-A expression (Figure 4E).
In order to verify the nuclear interaction of EGFR with
STAT5, an immunoﬂuorescence assay was performed.
As shown in Figure 5A, the EGFR was translocated
into the nucleus where it co-localized with STAT5 after
EGF stimulation. Western blot analysis indicated the
nuclear co-localization of EGFR and STAT5 in puriﬁed
cell fractions (Figure 5B). The co-immunoprecipita-
tion assay coupled with an immunoblot analysis also
showed the nuclear interaction between EGFR and
STAT5 (Figure 5C). These data strongly support the
notion that the nuclear translocation of EGFR and
STAT5 is signiﬁcantly enhanced by EGF stimulation. It
was also established that the EGFR can physically interact
with STAT5 in the nucleus.
The EGFR and STAT5are important forEGF-induced
Aurora-A gene expression
Since the nuclear EGFR can interact with STAT5 in the
activation of Aurora-A gene expression, we next tried to
verify the importance of EGFR and STAT5 in EGF-
induced Aurora-A expression by an siRNA assay. The
eﬃciency of the EGFR and STAT siRNA was ﬁrst
tested. Immunoblot analysis revealed that the EGFR
siRNA possesses the ability to substantially attenuate
expression of the EGFR, and the ability and speciﬁcity
of STAT5A and STAT5B siRNA were also examined
(Figure 6A). In addition, the control siRNA did not
reduce expression of the EGFR, STAT5A or STAT5B
(Figure 6A). As shown in Figure 6B, when the EGFR or
STAT5A proteins were reduced, the eﬀect of EGF-induced
Aurora-A expression dropped, whereas STAT5B siRNA
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Nucleic Acids Research, 2008, Vol. 36, No. 13 4345did not inﬂuence the eﬀect of EGF-induced Aurora-A
expression (Figure 6B). The reporter assay also demon-
strated that EGF-induced Aurora-A promoter activation
was reduced by EGFR siRNA and STAT5A siRNA
(Figure 6C). When Myc-STAT5A was ectopically
expressed, the induced expression of Aurora-A by EGF
was enhanced, and also Aurora-A promoter activity was
increased by EGF stimulation (Figure 6D). To further
demonstrate the speciﬁc role of STAT5A, but not
STAT5B, in the induction expression of Aurora-A under
EGF stimulus, a second STAT5A siRNA species was used
to rule out the possibility of siRNA oﬀ targeted eﬀect,
and a rescue experiment was also performed. The result
showed that the expression of a siRNA-insensitive
Myc-STAT5A can restore the decreased activity of
Aurora-A promoter in the STAT5A knockdown cells
under EGF treatment (Figure 6E). In order to further con-
ﬁrm the cooperative eﬀect of EGFR and STAT5A in
induction the expression of Aurora-A, EGFR and
STAT5A were co-transfected into a no EGFR expressed
CHO (Chinese hamster ovary) cells (23). The data indi-
cated that ectopic expression of STAT5A or EGFR, but
not the STAT5B, can increase the promoter activity of
Aurora-A. Moreover, co-expression of STAT5A and
EGFR has a synergic eﬀect in increase Aurora-A promoter
activity, whereas co-expression of STAT5B and EGFR has
not (Figure 6F). Most importantly, the recruitment of
nuclear EGFR to Aurora-A promoter was abolished in
the STAT5A knockdown cells (Figure 6G, lane 5), but
not in the control and STAT5B knockdown cells
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and immunoprecipitation/Western blot assay (C) using the indicated antibodies.
4346 Nucleic Acids Research, 2008, Vol. 36, No. 13(Figure 6G, lanes 4 and 6). Therefore, these results suggest
that the EGFR and STAT5A play critical roles in EGF-
induced Aurora-A gene expression.
DISCUSSION
In this study, we put forth the idea that in some EGFR-
expressing cancer cells, the activated EGFR can be
translocated to the nucleus to serve as a transcriptional
activator and cooperate with STAT5 to enhance the
expression of Aurora-A. The overexpressed Aurora-A
may result in centrosomes ampliﬁcation and microtubule
disorder, both of which are critical steps for aneploidy and
chromosome instability, ultimately leading to tumor for-
mation. It is well recognized that the expression of
Aurora-A is cell-cycle-dependent and is involved in cen-
trosome functions including maturation, duplication and
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Nucleic Acids Research, 2008, Vol. 36, No. 13 4347separation as well as spindle assembly and stability.
Therefore the accurate control of Aurora-A expression
may be very important for maintaining genetic stability
(35). In addition, it was reported that the EGFR is over-
expressed in some malignant tumors, and the overex-
pressed EGFR can be detected in the nucleus where it
serves as a transcriptional activator (17,21). This phenom-
enon is highly correlated with cell proliferation (21).
Furthermore, the constitutively activated EGFR is
thought to play a role in chromosome instability (27,28).
These descriptions encouraged us to investigate whether
any possible correlation between overexpressed EGFR
and Aurora-A exists in tumor cells.
It is known that the activated EGFR carries out its
biological eﬀects via two signaling pathways: the cytoplas-
mic/traditional pathway and nuclear pathway (34).
Activation of the cytoplasmic/traditional EGFR pathway
leads cells to tumorigenesis, metastasis, high proliferation
and resistance to chemotherapy and radiation. In some
cases, the membrane EGFR is translocated into the
nucleus by ligand stimulation, and after nuclear transloca-
tion, the nuclear EGFR interacts with other transcrip-
tional factors, which possess DNA-binding ability,
thus activating gene expression (34). There are a lot of
reports indicating that nuclear localization of the EGFR
is highly correlated with tumor malignancy, cell prolifera-
tion, cell-cycle progression and patient survival (34,36).
The nuclear importation of the membrane receptor was
not only observed for the EGFR, but also for many
other receptor tyrosine kinases, such as HER-2 (25,37),
FGFR (38), HER-3 (39) and cytokine receptors (40).
In this study, EGF enhanced Aurora-A gene expres-
sion only in EGFR-expressing cell lines. The activated
EGFR was located into the nuclei of these tested cells
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4348 Nucleic Acids Research, 2008, Vol. 36, No. 13(Figures 3B and 5A), and cooperated with STAT5 to
enhance Aurora-A gene expression (Figure 4).
STAT5 is activated by many growth factors and cyto-
kines (41), thereby suggesting the involvement of STAT5
in growth signaling. Activation of STAT5 is correlated
with cell proliferation and diﬀerentiation. Although the
target genes which are activated by STAT5 in pathogen-
esis are consistent with normal cells, constitutive activa-
tion of STAT5 leads to target gene overexpression,
resulting in enhanced expression of anti-apoptosis and
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Nucleic Acids Research, 2008, Vol. 36, No. 13 4349cell-cycle progression genes (41). There are two STAT5
proteins, STAT5A and STAT5B, which are encoded by
two distinct but closely related genes. STAT5A has a
higher DNA-binding aﬃnity than STAT5B, and it is
mostly involved in prolactin-directed mammary gland
maturation (42), whereas STAT5B is believed to be
involved in the response to the growth hormone (42).
This study is the ﬁrst report to demonstrate that STAT5
can transactivate the expression of the Aurora-A gene. To
our surprise, according the results, only STAT5A not
STAT5B was involved in EGF-induced Aurora-A overex-
pression (Figure 6). This is an additional evidence to prove
that STAT5A and STAT5B may participate in diﬀerent
cell functions.
It was previously reported that the EGF can induce
rapid centrosomal separation, but the underlying mecha-
nism was not clear (43). Based on this study, we believe
that Aurora-A kinase may be the major player causing
centrosomal separation which ultimately results in centro-
somes ampliﬁcation under EGF stimulation. It is well
recognized that the EGFR and Aurora-A are overex-
pressed in many cancers (44,45), and this is the ﬁrst
study to examine their correlation. By treating cells with
the EGFR-speciﬁc inhibitor, AG1478, the EGFR could
not further activate or induce Aurora-A gene expression
(Figure 3A). When the endogenous EGFR was decreased
by the siRNA technique, EGF-induced Aurora-A overex-
pression was also attenuated (Figure 6B). These results
support the notion that the activated EGFR indeed
plays a role in activating Aurora-A gene expression.
This study demonstrated that the nuclear EGFR can
cooperate with STAT5A to target the promoter region
of Aurora-A and enhance its expression in cancer cells.
The nuclear EGFR hence may indirectly play a functional
role in cell proliferation and chromosome instability.
These results further provide a link between the activated
EGFR and chromosomal instability. However, we cannot
rule out the possibility that the eﬀect of the traditional/
cytoplasmic EGFR signaling pathway on EGF-induced
Aurora-A overexpression. In fact, LS174T cells, which
express the membrane EGFR (Figure 2B), underwent
EGFR endocytosis after EGF stimulation (data not
shown), but the phenomena of EGF-induced Aurora-A
overexpression also existed in these cells (Figure 2B).
The traditional membrane EGFR pathway transduces
the extracellular signals into the nucleus through activa-
tion of multiple signaling cascades, whereas the nuclear
EGFR pathway directly transmits extracellular signals
from the cytoplasmic membrane to its target genes in
the nucleus (34). How cells determine the fate of the
EGFR to undergo the cytoplasmic or nuclear pathway
remains largely unknown. It was reported that the nuclear
localization of receptor tyrosine kinases is growth-factor-
dependent and may play a role in transcriptional activa-
tion (17). There are many reports indicating that the
pathological and clinical importance of a cellular protein
is not only dependent on its expression level but also on its
subcellular localization (36). Nuclear localization of the
EGFR is usually co-expressed with Ki-67 and cyclin D
(36), both of which are indicators of cell proliferation.
Therefore, detection of the nuclear EGFR may indicate
a poor survival rate in cancer patients and activated cell
proliferation (36). However, using an immunohistochem-
istry assay, the expressions of Aurora-A and the EGFR in
breast and colorectal cancer tissues were analyzed, and
our preliminary results indicated that overexpression of
Aurora-A has a correlation trend with EGFR expression,
of around 66.67% (10/15) in breast cancers and 75%
(9/12) in colorectal cancers (Hung, L.Y. et al., unpub-
lished data). Combined with the siRNA data (Figure 6),
we concluded that the EGFR is indeed involved in EGF-
induced Aurora-A expression.
In recent years, an EGFR mAb has been used to treat
many types of cancer patients (46), including colorectal
cancers (47,48). The small molecular inhibitor of the
Aurora kinases is also used to treat acute myelogenous
leukemia and chronic myelogenous leukemia (49,50).
Although it was reported that the EGFR and Aurora-A
are overexpressed in many cancers, including colorectal,
breast and lung cancers, none of them provided a linkage
between them. This report may provide new insights
for cancer therapeutics targeting both the EGFR and
Aurora-A in cancer therapy.
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